SavedAdd your journal

Journals / Klinik Psikofarmakoloji Bülteni / 2009 / Cilt: 19 - Sayı: 3

Oral antipsikotik ilaç kullanımına uyumsuz şizofreni hastalarında uzun etkili risperidon enjeksiyon tedavisinin etkinliğinin retrospektif olarak incelenmesi

The effectiveness of risperidone long-acting injection in oral antipsychotic non-adherent patients with schizophrenia: A retrospective study

Şengül CANGÜR
Ayşegül AYDIN
Asıl SARANDOL
Vahap Ozan KOTAN
Selçuk KIRLI
Cengiz AKKAYA
Pages
255–262
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For 11 patients (36.7%), oral add-on antipsychotic treatment (OAT) was discontinued after the 3rd injection of risperidone (No-OAT group); for 19 (63.3%), it was continued (OAT group).Results: The proportion who discontinued medications was 46.7% overall; it was 45.5% for OAT and 47.4% for No- OAT groups (P=0.781).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To determine effectiveness and adherence to risperidone long-acting injection (RLAI) in schizophrenic patients who were non-adherent to oral antipsychotic treatment.
📊
Key Findings & Data:Method: We retrospectively checked over 30 schizophrenic patients (12 males, mean age=36.1±9.5 years) who were hospitalized for relapse of their disorder due to non-adherence to oral antipsychotic drugs.
💡
Conclusion & Impact:For 11 patients (36.7%), oral add-on antipsychotic treatment (OAT) was discontinued after the 3rd injection of risperidone (No-OAT group); for 19 (63.3%), it was continued (OAT group).Results: The proportion who discontinued medications was 46.7% overall; it was 45.5% for OAT and 47.4% for No- OAT groups (P=0.781).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To determine effectiveness and adherence to risperidone long-acting injection (RLAI) in schizophrenic patients who were non-adherent to oral antipsychotic treatment. Method: We retrospectively checked over 30 schizophrenic patients (12 males, mean age=36.1±9.5 years) who were hospitalized for relapse of their disorder due to non-adherence to oral antipsychotic drugs. Assessment tools were Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Positive Symptoms (SAPS), Scale for Assessment of Negative Symptoms (SANS) and Simpson-Angus Scale (SAS). Mean follow-up was 236.1±121.0 (28 336) days. For 11 patients (36.7%), oral add-on antipsychotic treatment (OAT) was discontinued after the 3rd injection of risperidone (No-OAT group); for 19 (63.3%), it was continued (OAT group).Results: The proportion who discontinued medications was 46.7% overall; it was 45.5% for OAT and 47.4% for No- OAT groups (P=0.781). Mean BPRS, SAPS, SANS, and SAS scores decreased significantly from baseline during follow- up. The No-OAT group had a greater decrease (percent change in BPRS from baseline) than the OAT group at the 3rd , 6th , 9th , 10th , 11th , 12th , 13th , 15th and 17th visits; for SANS, it was greater at the 6th and 10th visits (P

Özet

Amaç: Bu çalışmada, oral antipsikotik ilaç kullanımına uyum göstermeyen şizofreni hastalarında uzun-etkili risperidon enjeksiyon tedavisine uyum ve tedavi etkinliğinin belirlenmesi amaçlanmıştır.Yöntem: Mevcut oral antipsikotik tedavisine tam veya kısmi uyumsuzluğa bağlı relaps nedeniyle kliniğe yatırılmış olan 30 şizofreni hastası (12 erkek, ortalama yaş=36.1±9.5 yıl) retrospektif olarak incelenmiştir. Kısa Psikiyatrik Değerlendirme Ölçeği (BPRS), Pozitif Semptomları Değerlendirme Ölçeği (SAPS), Negatif Semptomları Değerlendirme Ölçeği (SANS) ve Simpson-Angus Ölçeği (SAS) değerlendirme amacıyla kullanılmış ölçeklerdir. Ortalama izlem süresi 236.1±121.0 (28 336) gündü. On bir hastada (%36.7) uzun etkili risperidon enjeksiyon tedavisiyle birlikte başlanan ek oral antipsikotik tedavi üçüncü risperidon enjeksiyonunu takiben kesilebilmişken (No-OAT grubu), 19 hastada (%63.3) ek oral antipsikotik tedaviye devam edildi (OAT grubu).Bulgular: Tüm hastalarda tedaviyi bırakma oranı %46.7 iken, bu oran OAT grubunda %45.5 ve No-OAT grubunda %47.4 (P=0.781) idi. Ortalama BPRS, SAPS, SANS ve SAS skorları izlem sürecinde belirgin olarak azaldı. Başlangıca göre BPRS skorlarındaki yüzdelik değişim açısından No-OAT grubunda 3, 6, 9, 10, 11, 12, 13, 15 ve 17. vizitlerde OAT grubuna göre daha fazla azalma olurken, SANS skorlarında No-OAT grubunda OAT grubuna göre 6 ve 10. vizitlerde daha fazla azalma oldu (Her ikisi için P

🔖

Cite This Article

CANGÜR, Ş., AYDIN, A., SARANDOL, A., KOTAN, V. O., KIRLI, S., AKKAYA, C. (2022). Oral antipsikotik ilaç kullanımına uyumsuz şizofreni hastalarında uzun etkili risperidon enjeksiyon tedavisinin etkinliğinin retrospektif olarak incelenmesi. Klinik Psikofarmakoloji Bülteni, Cilt: 19 - Sayı: 3, 255–262. https://ajindex.com/articles/574257

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
  2. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial. Schizophr Bull 2003; 29:33-43
  3. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 2001; 155:230-233
  4. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: Implications for treatment outcome. Acta Psychiatr Scand Suppl 1994; 380:27-32
  5. Dilbaz N, Karamustafalıoğlu O, Oral T, Önder E, Çetin M. Psikiyatri polikliniğine başvuran şizofreni hastalarında tedaviye uyumun ve uyumu etkileyen faktörlerin değerlendirilmesi. Klinik Psikofarmakoloji Bülteni -Bulletin of Clinical Psychopharmacology 2006; 4: 223- 231
  6. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47:741-773
  7. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: Clinical studies. J Clin Psychiatry 2003; 64 Suppl 16:34-40
  8. Yıldız M, Yüksel AG. Psikotik bozuklukların tedavisinde depo antipsikotik ilaç (flufenazin dekanoat) kullanımı neden hala önemlidir? Klinik sonuç açısından bir inceleme. Klinik Psikofarmakoloji Bülteni - Bulletin of Clinical Psychopharmacology 2006; 16: 98-103
  9. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179:290-299
  10. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64:1250-1257
  11. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004; 70:91-100
  12. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160:1125-1132. 13